2024-511325-67-00撤回3 期
The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 300
- 试验地点
- 12
- 主要终点
- eGFR slope calculated using eGFR values from randomisation to week 108
研究概览
简要总结
To determine investigational agents or combinations of agents that reduce the rate of eGFR decline (slow progression of CKD), compared to placebo, in patients with chronic kidney disease receiving standard of care therapy.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m^2)
- •Currently receiving standard of care treatment according to treating physician
- •Eligible for randomisation in at least one recruiting domain-specific appendix
- •Participant and treating physician are willing and able to perform trial procedures
- •Urine albumin-creatinine ratio (uACR) >200 mg/g or urine protein-creatinine ratio (uPCR) >300 mg/g from the most recent result in the previous 3 months.
- •On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening according to treating physician.
- •Treating physician believes finerenone is clinically appropriate for the participant.
- •Participant and treating physician are willing and able to perform Mineralocorticoid Receptor Antagonist Domain-Specific Appendix procedures.
排除标准
- •Currently receiving maintenance dialysis
- •Severe hepatic impairment (defined as Child-Pugh Class C)
- •Adrenal insufficiency
- •Currently pregnant or breast feeding, or intending to become pregnant
- •Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
- •Life expectancy less than 6 months
- •Recipient of kidney transplant
- •Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
- •Current treatment with mineralocorticoid receptor antagonist (MRA), where the treating physician or patient is not willing to discontinue this medication
- •Known allergy, intolerance or contraindication to MRAs
- •Current treatment with strong CYP3A4 inhibitors
- •Systolic BP <110 mmHg or diastolic BP <55 mmHg without antihypertensive therapy at time of screening
结局指标
主要结局
eGFR slope calculated using eGFR values from randomisation to week 108
eGFR slope calculated using eGFR values from randomisation to week 108
次要结局
- 3. Time to a composite outcome of ≥40% eGFR decline from randomisation or kidney failure
- 4. All-cause mortality at 108 weeks
- 5. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke) between randomisation and 108 weeks
- 1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between randomisation and 24 weeks, measured as a continuous variable
- 2. Composite outcome of proportion of participants experiencing a 40% eGFR decline between randomisation and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m^2 or chronic kidney replacement therapy start) at 108 weeks
- 6. Time to first occurrence of a cardiovascular event
- 7. Safety and tolerability of treatment
- 8. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDIS-CKD) at 6-monthly intervals from randomisation to week 108
- 9. The Mineralocorticoid Receptor Antagonist Domain-Specific Appendix has a domain-specific secondary outcome of time to the composite of ≥57% eGFR decline or kidney failure.
研究者
Sradha Kotwal
Scientific
The George Institute For Global Health
研究点 (12)
Loading locations...
相似试验
已完成
不适用
Efficacy and safety of the combination therapy with Ipragliflozin for the cases who have insufficient effect by oral hypoglycemic agentstype 2 diabetes mellitusJPRN-UMIN000016563ational Hospital Organization Kyoto Medical Center32
终止
1 期
Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver ImpairmentChronic Kidney DiseaseNCT04820621Bayer5
已完成
不适用
Effects of the Eefooton on eGFR and QoL in Chronic Kidney Disease Patients.Chronic Kidney DiseasesNCT04940117Kaohsiung Veterans General Hospital.100
已完成
不适用
Rapid Kidney Function Decline in Older AdultsKidney Function DeclineGlomerular Filtration RateUrine Albumin-creatinine RatioHealthy AgingComorbidityChronic Kidney DiseaseNCT06765811Huashan Hospital1,539
已完成
2 期
Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency PatientsSecondary HyperparathyroidismChronic Renal InsufficiencyNCT00042432Amgen54